Geode Capital Management
ACTU

Geode Capital Management’s Actuate Therapeutics ACTU Stock Holding History

Geode Capital Management’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$172K Sell
112,554
-115,777
-51% -$268K ﹤0.01% 3963
2026
Q1 		$626K Buy
228,331
+20,587
+10% +$85.3K ﹤0.01% 3510
2025
Q4 		$1.27M Buy
207,744
+62,332
+43% +$428K ﹤0.01% 3308
2025
Q3 		$973K Buy
145,412
+27,362
+23% +$198K ﹤0.01% 3386
2025
Q2 		$721K Buy
118,050
+84,561
+253% +$739K ﹤0.01% 3434
2025
Q1 		$227K Buy
33,489
+5,596
+20% +$44.9K ﹤0.01% 3801
2024
Q4 		$222K Hold
27,893
– – ﹤0.01% 3870
2024
Q3 		$208K Buy
+27,893
New +$221K ﹤0.01% 3891

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.87B AUM 24.49% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $306M AUM 15.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ADEF
ABS Direct Equity Fund Stamford, Connecticut $159M AUM 34.17% 1-Year Est. Return
AIM
ABS Investment Management Greenwich, Connecticut $159M AUM

Geode Capital Management's ACTU Position: Q2 2026 in Review

Geode Capital Management reduced its Actuate Therapeutics (ACTU) stake by 51% in Q2 2026, selling an estimated $268K and leaving 112,554 shares worth $172K. The position accounts for ﹤0.01% of the portfolio, ranked #3963.

Geode Capital Management first reported a position in ACTU in Q3 2024 and has held it in 8 quarters since. The position peaked at $1.27M in Q4 2025. 63 funds tracked by Wall St. Rank hold ACTU as of Q2 2026.

  • Geode Capital Management held 112,554 shares of Actuate Therapeutics worth $172K as of Q2 2026.
  • Geode Capital Management sold 115,777 Actuate Therapeutics shares in Q2 2026, an estimated $268K.
  • Actuate Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #3963 holding.
  • Geode Capital Management first reported a position in Actuate Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Geode Capital Management's Actuate Therapeutics position peaked at $1.27M in Q4 2025.
  • 63 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.